Oct. 12 (Bloomberg) -- Joshua Levine, who oversaw the sales of Mentor Corp. and Immucor Inc., has been named chief executive officer of Accuray Inc., the maker of radiation devices used to treat cancer.
Levine, 54, replaces Euan Thomson, who left the company after more than a decade, the Sunnyvale, California-based company said today in a statement. Thomson said a new CEO would be “healthy for the organization,” according to the statement.
Accuray’s stock, which has risen 66 percent this year before today, has been expanding its sales after last year acquiring TomoTherapy, which makes a 3D-imaging system for precisely targeting radiation.
Levine “is an experienced, commercially oriented CEO with diverse global health-care experience necessary to lead the company to the next level of success,” said Accuray Chairman Louis Lavigne in the statement.
Accuray fell 3.3 percent to $6.79 at 4 p.m. New York time.
Levine oversaw the sale of breast implant maker Mentor to J&J in 2009 for $1.1 billion. He was the CEO of Immucor, which makes reagents used in medical testing, last year when it was bought by TPG Capital for $2 billion.
To contact the reporter on this story: Shannon Pettypiece in New York at firstname.lastname@example.org;
To contact the editor responsible for this story: Reg Gale at email@example.com